OSI-906 In Clinical Trial For Adrenocortical Carcinoma
Links shared publicly online about this topic.
- 1,728total visits
OSI-906 In Clinical Trial For Adrenocortical Carcinoma
View full resource at medicalnewstoday.com
Tags: Cancer, Drug, Healthcare, Clinical Trial
Most Recently Shared on September 23, 2009 at 5:34 pm By:
OSI-906 In Clinical Trial For Adrenocortical Carcinoma: TGen Clinical Research Services at Scottsdale Healthcare.. http://bit.ly/nTvgp
Also Shared By:
Revolutionary drug could be new hope for adrenal cancer patients
physorg.com — “TGen Clinical Research Services at Scottsdale Healthcare today announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands.” View full resource at physorg.com
Most Recently Shared on September 22, 2009 at 5:06 pm By:
Revolutionary drug could be new hope for adrenal cancer patients http://bit.ly/aaLdN
OSI Pharmaceuticals Initiates Phase III Registration-Oriented Study For OSI-906 In Adrenocortical Carcinoma And Phase I/II Study In Ovarian Cancer
medicalnewstoday.com — “Osi pharmaceuticals, inc. (nasdaq: osip) announced today the initiation of two clinical trials with osi-906, the company's potential first-in-class, oral insulin-like growth factor-1 receptor (igf” View full resource at medicalnewstoday.com
Most Recently Shared on September 4, 2009 at 4:05 pm By:
OSI Pharmaceuticals Initiates Phase III Registration-Oriented Study For OSI-906 In Adrenocortical Carcinoma And .. http://bit.ly/2q4n5o
Advertisement
MNT Cancer News
@mnt_cancer
OSI Pharmaceuticals Initiates Phase III Registration-Oriented Study For OSI-906 In Adrenocortical Carcinoma And .. http://bit.ly/2q4n5o
1 year ago...